July 12, 2018: DuPont Safety & Construction (DuPont) has announced a formal alliance to collaborate on technical and market development in temperature monitoring, shipment tracking, asset management and ‘smart’ data-driven services. The company is a business unit of DowDuPont Specialty Products Division and the manufacturer of DuPont™ Tyvek® brand thermal cargo covers; and SkyCell, the Swiss-based manufacturer of temperature-controlled containers for food and pharmaceuticals. The combined effort is aimed at maintaining the physical and clinical integrity of pharmaceuticals in transit.

“DuPont is a firm believer in the potential of strategic alliances like this one where each party can leverage its respective strength for powerful solutions. There is a strong strategic fit between DuPont and SkyCell and we see this as an important step in complementing our Tyvek® Cargo Covers offering and expanding our market capability with high-performance solutions for an increasingly sophisticated pharmaceutical supply chain,” said Christian Marx, VP and GM of Tyvek® and Typar®.

The alliance will harness the strengths of two of the strongest names in the field of pharmaceutical cold chain to better define and meet the needs of customers around the world. Under the terms of the agreement DuPont will gain access to SkyCell’s remote temperature-management solutions and expertise and acquire marketing rights to the SkyCell portfolio of insulated shipping containers. The SkyCell containers will be marketed by DuPont alongside its Tyvek® products enabling the market-leader in cargo covers to provide an unrivalled breadth of high-tech temperature-management solutions to discerning customers. SkyCell, on the other hand, will be in a position to tap into the renowned technical resource of DuPont and will benefit from the DuPont global network especially in emerging markets and the Asia-Pacific region.

“With a shared vision of better leveraging data in the supply chain of sensitive pharmaceuticals, this partnership will help us play our part in ensuring that medicines, vaccines and other health-related treatments get to the final patients in a safe, sustainable and timely manner,” said Richard Ettl, CEO of SkyCell.